THE ROLE OF APOPTOSIS IN PREECLAMPSIA

Levy R

Department of Obstetrics and Gynecology, Kaplan Medical Center, affiliated to the Hebrew University School of Medicine.

Running title: Apoptotic processes are involved in the pathophysiology of preeclampsia

Key words: Apoptosis, preeclampsia, placenta, hypoxia, p53.

Correspondence:

Roni Levy, MD, Department of Obstetrics and Gynecology, Kaplan Medical Center
Tel: 08-9441558, 050-903984. Fax: 08-9467045. E mail: Roni_L@clalit.org.il
Preeclampsia occurs in 5-7% of pregnancies and is a major cause of perinatal and maternal morbidity and mortality worldwide. Preeclampsia is a condition specific to pregnancy presenting with a clinical picture of hypertension, proteinuria and different systemic manifestations. Despite intensive research the pathophysiology leading to the consequences of preeclampsia remain elusive. The most accepted concept is that immune maladaptation to the fetal allograft causes defective placentation. During preeclamptic pregnancy cytotrophoblast invasion of the myometrium is abnormally shallow, and remodeling of the uterine spiral artery is incomplete. Many vessels are occluded by atherosis, with an accumulation of lipid-laden macrophages and a perivascular mononuclear cell infiltrate. The net result is uteroplacental ischemia.

A yet undefined toxic circulating factor released by the ischemic placenta enters the maternal circulation and damages vascular endothelium and is responsible for the clinic disease characterized by impaired endothelial function [1]. This circulating factor may be specific upregulated protein, cellular debris or free fetal DNA.

Numerous articles have been published addressing the association between altered apoptosis and preeclampsia [2-7]. Apoptosis has been linked to preeclampsia at different steps in the proposed pathway leading to the clinical manifestation of preeclampsia. At each of these steps, apoptosis may play a central role.

The term apoptosis, Greek for “falling off”—like autumn leaves—coined by Kerr, Wyllie and Currie in 1972 [8], is descriptive of a unique morphology of cell death. It is distinct from cell death by necrosis, where damage to groups of cells, cytoplasmic swelling and inflammatory processes are characteristic. Unlike necrosis, apoptosis includes chromatin condensation with nuclear fragmentation and cytoplasmic condensation with cell shrinkage. The morphological changes may be part of normal physiology or may be secondary to pathological insult. Apoptosis occurs during
normal embryonic development and in the turnover of mature tissues. However, apoptosis is also found in tissues exposed to exogenous stimuli, such as hypoxia or cytotoxic agents, and it can be induced by ligand-receptor interactions, such as with Fas and TNF-α [9]. Apoptosis is described in many physiological as well as pathological processes in the human body, including preeclampsia with or without fetal growth restriction (FGR). It may be argued that enhanced apoptosis may be a normal response to stimuli such as hypoxia. However, several in-vitro and in-vivo studies showed that specific and unspecific scavengers of apoptosis such as caspase inhibitor and Epidermal growth factor decreased the level of apoptosis and improved the tissue function [10-12]. These studies point to an important role of apoptosis in pathologic processes.

In this article, I review the evidence linking apoptosis to each step in the mechanism of preeclampsia (Fig. 1).

**Altered apoptosis induces maternal immune intolerance toward the fetus**

The fetus and placenta are considered a semi-allograft to the mother’s immune system and consequently generate an immune rejection response. From early pregnancy, there is a large influx of macrophages and lymphocytes into the decidua at the maternal-fetal interface such that white blood cells comprise up to 40% of the cells found in the decidua during pregnancy [13]. How is the developing fetus protected from these cells? One of the most accepted theories is that Human Leukocyte Antigen (HLA) –G has an immunologically permisive role of the antigenic mismatch between mother and fetus [14]. HLA-G expression was found to be defective in extravillous cytotrophoblast of preeclamptic placentas. Further, the serum levels of a soluble HLA-G1 isoform who downregulates T cell and NK activity by
inducing apoptosis, were decreased in preclamptic patients [14]. The exact mechanism by which HLA-G causes cell apoptosis is unknown.

Another theory that are taken from other systems of the body that are "immunologically privileged sites". The anterior chamber of the eye and the testes are protected from antigens which penetrate these sites and fail to elicit an immune response. It turns out that cells in these sites differ from the other cells of the body in that they express high levels of FasL at all times. Thus antigen-reactive T cells, which express Fas, would be killed when they enter these sites[15]. Fas, a 45-kDa surface protein which is a member of the tumor necrosis factor superfamily, induces cell apoptosis upon binding to the ligand FasL [16]. Several pieces of evidence point to the key role played by the Fas-FasL system in protecting the fetus from maternal immune system [17]. The trophoblast of first-trimester placentas expresses FasL, while Fas antigen is localized mainly on decidual cells, in particular the maternal leukocytes [18,19]. When trophoblasts expressing FasL are exposed to activated lymphocytes in-vitro, they induce lymphocytes apoptosis [20]. In mice, FasL is positioned to prevent the exchange of activated immune cells between the mother and the fetus, and deters trafficking of activated Fas-expressing immune cells at the maternal-fetal interphase [21]. Mice lacking FasL (gld) exhibit leukocyte infiltration of the decidual-placental interface and increased fetal loss. In preeclampsia, decidual cells exhibit lower expression of Fas antigen [6], and lower expression of FasL is seen on trophoblast cells [4]. In addition, the level of serum-soluble Fas (sFas) antigen is elevated in the maternal circulation [6]. sFas, a spliced product of the Fas antigen, does not stimulate apoptosis; rather, it protects cells from apoptosis by competitive binding to the Fas antigen. Thus, elevated levels of sFas in the maternal circulation concomitant with lower expression of Fas and FasL result in diminished apoptotic
deletion of the lymphocytes in the maternal decidual system. As a consequence, there is increased apoptosis and trophoblast damage in the fetal placental compartment. Indeed, samples taken from the uterine wall of preeclamptic women demonstrated excess of macrophages. These macrophages when exposed to TNF-α, a known stimulator of placental apoptosis [22], may limit trophoblast invasion of spiral arterial segments by TNF-α mediate apoptosis [23]. Indeed TNF-α is found in high concentration of plasma, amniotic fluid and placental tissue of patients with preeclampsia [24,25]. The enhanced apoptosis of the invading trophoblasts results in limited invasion of the spiral arteries due to reduced activity of the cytotrophoblasts, so that myometrial segments of the spiral arteries remain intact resulting in the formation of an arteriolar system with high resistance. The failure of trophoblast invasion results in a reduction in uteroplacental perfusion, with the placenta becoming increasingly ischemic as gestation progresses. Placentas from women with preeclampsia display an increased frequency of placental infarcts and altered morphology, evidenced by abnormal cytotrophoblast proliferation and increased formation of syncytial knots [26]. In a study [27] comparing tissue samples of the villus-uterus attachment, taken from preeclamptic and control patients, samples from the former showed widespread apoptosis, while those from normal pregnancies had a low rate of apoptotic cells. Further, the samples taken from preeclamptic patients showed lower expression of one of the proapoptotic proteins, Bcl-2. Increased apoptosis along with decreased expression of Bcl-2 has also been reported in myocardial cells [12]. Thus, excess apoptotic activity in placental bed of preeclamptic women inhibits trophoblast invasion into the spiral artery by increasing trophoblast apoptosis.
Several mechanisms, in addition to apoptosis, have been reported to limit extravillous invasion of the placental bed. These consist of the reduced expression of various proteins, among them integrin $\alpha_1/\beta_1$, matrix metalloproteinase, vascular cell adhesion molecules, Vascular endothelial growth factor (VEGF) and heparin-binding Epidermal growth factor (EGF) [28]. A reduction in the expression of these proteins necessary for extravillous trophoblast differentiation along the invasive pathway is compatible with the view that cells entering the apoptotic cascade downregulate their levels of protein transcription.

**Hypoxia induces placental apoptosis**

Placental ischemia secondary to defective placentation may be a prerequisite for the development of preeclampsia. Human term trophoblasts exposed to hypoxia in vitro exhibit enhanced apoptosis [11]. The process was associated with increased expression of the proapoptotic proteins p53 and Bax and reduced expression of the antiapoptotic Bcl-2. Enhanced apoptosis and upregulation of p53 were also found in placental samples taken from pregnancies complicated by preeclampsia [29]. Hypoxia triggers apoptosis via a mechanism that involves predominantly mitochondrial pathways, as opposed to ligand-receptor pathways which are mediated by cytokines such as TNF-\(\alpha\) or Fas ligand (Fig 1). In this pathway, death signals are stimulated via modulation of the expression of specific apoptotic-related genes such as p53 and proteins of the Bcl-2 family. p53 plays a pivotal role in the cellular response to DNA damage, halting the cell cycle to allow repair of DNA. If repair is not possible, p53 promotes apoptosis. p53 is an unstable protein with a short half-life: exogenous stimuli such as hypoxia and oxidative stress stabilize it. p53 plays an important role in hypoxia-induced cell death in diverse cell types, including cardiocytes, hepatocytes.
and neuronal cells [30]. p53 expression is enhanced in cultured trophoblasts exposed
to hypoxia [11] as well as in placental biopsies taken from pregnancies complicated
by preeclampsia and FGR.

Hypoxia may not be the sole inducer of placental apoptosis. Oxidative free radicals
are frequently, although not universally, increased in preeclampsia [1]. Retention of
vasoreactivity of the spiral arteries caused by defective placentation may result in
intermittent perfusion of the intervillous space, fluctuating oxygen tension, and
ischemia-reperfusion insult of the villus. This oxidative stress may be associated with
enhanced placental apoptosis and increased turnover of the syncytiotrophoblast [31].

Thromboxane A2 levels are elevated in the circulation of pregnant preeclamptic
women and in the placental villi [32]. Elevated levels of thromboxane A2 are
associated with thrombocyte aggregation, which may create a predisposition to
enhanced thrombosis and infarct injury of the placenta. Thromboxane A2 has been
recently found to enhance apoptosis in primary-term human trophoblasts [33].

**Placental apoptosis increases syncytiotrophoblast deportation**

One of the unsolved questions in the pathogenesis of preeclampsia is the link
between placental ischemia and endothelial cell dysfunction. Systemic endothelial
damage appears to be the central theme in the signs and symptoms of preeclampsia.
One of the theories, presented by Redman and Sargent [34], is that systemic
endothelial damage is caused by microdeposition of syncytiotrophoblast microvillous
membrane particles. These particles can be detected in the plasma of normal
pregnancies but increase in women with preeclampsia. The increased
syncytiotrophoblast deportation in preeclampsia may be caused by enhanced
apoptosis at the syncytium affecting the integrity of the tissue. It has been proposed
that apoptosis plays an important role in the renewal of the syncytium [35,36]. Apoptotic nuclei are found in syncytial knots and probably contribute to the shedding of syncytial fragments into the maternal circulation [37]. This process is enhanced in the syncytium of placentas from pregnancies complicated by preeclampsia [6,29]. When the maternal circulation cannot compensate for this enhancement, systemic endothelial damage occurs.

Altered apoptosis in preeclampsia is found not only in the placenta but also in the endothelial cells [38]. Endothelial-tissue apoptosis may occur from the toxic effect of excessive syncytial fragments, but it may also occur from the local hypoxic enviroment caused by the constriction of efferent blood vessels or from the effect mediated by free radicals. This effect may occur via p53-mediated endothelial apoptosis, as found in other systems (11,12). Another hypothesis is that increased secretion of TNF-α induces activation and apoptosis of endothelial tissue [39]. Another hint for the apoptosis induced trophoblast microfragments deportation is the increased level of free DNA in the circulation of patient with preeclampsia [40].

In summary, altered apoptosis is involved in each step of the pathogenesis of preeclampsia. While deficient apoptosis may induce a maternal immune response against the fetus, enhanced apoptosis may interfere with the process of placentation, placental ischemia and subsequently, systemic endothelial damage. Thus, treatment modalities to inhibit or accelerate apoptosis cannot be employed in early pregnancy for prevention. Later in pregnancy, it would make sense to test treatments modalities that inhibit hypoxia mediated apoptosis in patients who early testing, such as abnormal Doppler of the uterine artery, indicates the initiation of preeclampsia. This however has to be first tested in animals models.
Since multiple different mechanisms, rather than a single factor, could contribute to the development of apoptosis, further studies to clarify the signaling mechanisms of apoptosis in preeclampsia should be conducted before any investigational treatment modalities are employed.
References


40. Levine RJ, Qian C, Leshane Es, Yu KF, England LJ, Schisterman EF, Wataganara T, Romero R, Bianchi DW. Two stage elevation of cell-
Figure 1. Apoptotic pathways. There are two main apoptotic pathways. One induced by internal or external stimuli mediated by proteins from the Bcl-2 family, via the mitochondria, the other through ligand to receptor stimuli such as Fas and TNF-α.
Figure 2. Apoptosis and sequences of preeclampsia.